Table 1.
Association of YBX1 expression with outcomes and biomarkers in human malignanciesa
| Human malignancies | Biomarkers associated with YBX1 | No. of published papersb |
|---|---|---|
| Breast cancer | ABCB1, EGFR, HER2, E2F‐1, CDC6, ER, EGR‐1, ER effector genes | 19 |
| Lung cancer | PCNA, HER2, HER3, CDC25a, MACC1 | 7 |
| Ovarian cancer | CD44, ABCB1, LRP/MVP, amphiregulin | 7 |
| Prostate cancer | AR | 6 |
| Colorectal cancer | EGFR, topoisomerase IIα, PCNA | 5 |
| Gastric cancer | HER2, CDC6 | 4 |
| 16 different tumor typesc | ABCB1, EGFR, HER2, EXH2, Cyclin A1/D1, AKT, LRP/MVP | 1‐3/each cancer |
Augmented nuclear and/or total (nuclear/cytoplasmic) expression of YBX1 predicts poor outcomes in patients with human malignancies in close association with aberrant expression of various biomarkers and genes. Poor outcomes are mainly assessed using overall survival or disease‐free survival, but some reports referred to histological grade, tumor grade, and metastasis.
References are listed in Doc S1.
Additional 16 tumor types include diffuse large B‐cell lymphoma, uterine cervical cancer, hepatocellular carcinoma, renal cell carcinoma, osteosarcoma, glioblastoma, nasopharyngeal carcinoma, laryngeal squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, thyroid neoplasm, melanoma, rhabdomyosarcoma, synovial sarcoma, neuroblastoma, and non‐Hodgkin lymphoma.
AR, androgen receptor; EGFR, epidermal growth factor receptor; EGR‐1, early growth response protein 1; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PCNA, proliferating cell nuclear antigen; YBX1, Y‐box binding protein‐1.